

AD _____

Award Number: W81XWH-04-1-0480

TITLE: An Organotypic Liver System for Tumor Progression

PRINCIPAL INVESTIGATOR: Alan Wells, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Pittsburgh
Pittsburgh, PA 15260

REPORT DATE: April 2005

TYPE OF REPORT: Annual

20060215 163

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-04-2005		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Apr 2004 - 31 Mar 2005	
4. TITLE AND SUBTITLE An Organotypic Liver System for Tumor Progression				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0480	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Alan Wells, M.D., Ph.D. E-mail: wellsa@upmc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pittsburgh Pittsburgh, PA 15260				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Our overall objective is to understand which tumor cell behaviors contribute to invasion and metastasis. This would allow rationale approaches to limit these aspects of tumor progression. While great strides have defined critical molecular determinants, the current experimental models of tumor invasion limit the dissection of complex cellular responses. <i>In vitro</i> assays do not capture tumor/host relations or relevant tissue architecture and physiology. <i>In vivo</i> model systems provide the relevant organism contexts but cannot readily be manipulated. Quantal advances would be enabled by combining the best attributes – direct manipulation of tumor and host, long-term visualization, and tissue relevant architecture. Our central premise is that an ex vivo organotypic liver tissue system can provide an environment to study tumor cell invasion and metastasis. Our objective is to utilize a physiologically relevant microreactor that has proved suitable for organotypic liver culture to investigate metastatic seeding. The sub-millimeter scale of this liver allows for real-time imaging over weeks in culture. We established this system to determine what step is rate-limiting for tumor progression. We are now most finished with the first step in gaining this capability of establishing an organotypic liver tissue culture that supports metastatic establishment and growth.					
15. SUBJECT TERMS Tumor metastasis, novel technology, liver, bioreactor					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 9	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusions.....	8
References.....	9

AN ORGANOTYPIC LIVER SYSTEM FOR TUMOR PROGRESSION

Alan Wells, Linda Griffith, Donna Stolz, Douglas Lauffenburger

INTRODUCTION

Our overall objective is to understand which tumor cell behaviors contribute to invasion and metastasis. This would allow rationale approaches to limit these aspects of tumor progression. While great strides have defined critical molecular determinants, the current experimental models of tumor invasion limit the dissection of complex cellular responses. *In vitro* assays such as transmigration of barrier matrices or cell layers allow for targeted perturbations, but do not capture tumor/host relations or relevant tissue architecture and physiology (1). *In vivo* model systems, mainly xenografts and induced tumors, provide the relevant organism contexts but cannot readily be manipulated. Recent advances in imaging of tumors in living animals aids in documenting events, though these views still occur only over hours and only near the surface of observation (2). Thus, quantal advances would be enabled by new assay systems that combine the best attributes of both – direct manipulation of tumor and host, long-term (days to weeks) visualization, and tissue relevant architecture.

Our central premise is that an ex vivo organotypic liver tissue system can provide an environment to study tumor cell invasion and metastasis. Our objective is to utilize a physiologically relevant microreactor that has proved suitable for organotypic liver culture (3) to investigate cellular and molecular events during tumor metastatic seeding. The sub-millimeter scale of this liver allows for real-time imaging throughout the entire tissue over weeks in culture. We propose to use this system to determine when and how motility is rate-limiting for tumor progression. The first step in gaining this capability, and the one supported by the DoD funds is to determine whether an organotypic liver tissue culture supports metastatic establishment and growth.

BODY

The revised and accepted Statement of Work (Table 1) described a series of tasks to accomplish the one accepted Objective. We have tackled these Tasks in the order of greatest yield so that work in areas can progress as systems are being optimized in others. The main efforts during the first year of this two-year project have been focused on the establishing system for the tumor cells. The progress during this first year has put us in good position to accomplish the tasks within the time-frame provided.

Table 1. Statement of Work

Work to be performed at University of Pittsburgh (Wells and Stolz Laboratories):

1. isolate hepatocytes and endothelial cells
2. label tumor cells
3. seed bioreactors with cells
4. seed organotypic liver bioreactors with tumor cells

Work to be performed at MIT (Griffith and Lauffenburger Laboratories):

5. design bioreactor scaffolds for high volume production
6. optimize new bioreactor for continuous two-photon imaging
7. produce bioreactor scaffolds
8. deconvolute images to determine tumor-hepatocyte involvement and growth dynamics

Work to be performed at University of Pittsburgh:

Task 1. Isolate hepatocytes and endothelial cells. This task is now established. We have been successfully isolating both hepatocytes and endothelial cells as viable cells. These have been isolated both from wild-type rats and from GFP-expressing rats. These have been incorporated into the pre-bioreactor spheroids (Figure 1). We routinely obtain over 80% viability in these preparations. This is sufficient for generating the organotypic culture system.

Figure 1. The rat endothelial cells (vitaly stained red by di-I uptake, and labelled SEC in figure) are alive within the hepatocyte spheroids (nuclei of all cells stained blue by DAPI; hepatocytes are identified by morphology and labelled heps) prior to loading of the bioreactor.





Figure 2. MCF7 breast cancer cells fluorescing red from stable expression of RFP. RFP-expressing cells were selected by flow cytometry and passaged in culture for over 3 weeks. Virtually all cells express fluorescence demonstrating feasibility of following these cells for up to a month in the bioreactor.

selecting for stable expression of RFP in SKBr3 and MDA-361 breast carcinoma cells and hMEC nontransformed breast epithelial cells. These should be established by the early part of the second year of funding.

Task 2. Label tumor cells. During this first year we established MCF7 cells stably expressing RFP in addition to GFP (Figure 2). We are currently

Task 3. Seed bioreactors with cells. This task has been fully established. We have moved to generating liver bioreactors with transgenic hepatocytes and/or endothelial cells expressing GFP to better image the interactions with the tumor cells. These cells form bioreactor structures indistinguishable from non-transgenic cells (Figure 3). As the hepatocytes have an endogenous fluorescence in the same channel as GFP, this interfered with imaging tumor cells in this channel. As such, we have switched our tumor cell imaging to the red channel with RFP.




Figure 3. The hepatocytes and non-parenchymal cells from the GFP-transgenic rats establish channel-filled organoid cultures in the bioreactor similar to non-GFP-transgenic animal cells, as shown here 5 days after seeding.

Task 4. Seed organotypic liver bioreactors with tumor cells. This task is under development. We have accomplished this task with prostate tumor cell lines (Figure 4), as these studies were initiated prior to the current proposal. The tumor cells proliferate over a few day period to eventually take over the entire bioreactor. Interestingly, the prostate tumor cells do not grow in the absence of hepatocytes and in a 3D environment (Figure 5).

The newer bioreactor scaffolds that are higher volume production also enable better histological and electron microscopic examinations. However, seeding of tumor cells in these bioreactors requires different flow conditions. A posteriori, we have optimized the flow conditions to enable tumor cell seeding in these bioreactors.





Figure 4. The RPF-labelled tumor cells expand from a few isolated cells (red) among the hepatocytes (green) noted 2 days after seeding the bioreactor (left image), to form the predominant cell mass a week later (right image). Shown are images from the identical bioreactor channel; these are representative of over 50 total channels in at least 6 independent experiments.

Figure 5. The tumor cells do not proliferate in the absence of the liver bioreactor milieu under the same culture conditions of the bioreactor. The cells survive but do not increase in number in 2D cultures even in the presence of hepatocytes and collagen.



Work to be performed at MIT:

Task 5. Design bioreactor scaffolds for high volume production. The original bioreactor format was designed for in situ 2-photon imaging and requires a substantial technical effort to seed and run each individual reactor. This approach may be acceptable for 2-photon imaging, but there are other assays of interest that are desirable to perform on a high-throughput basis in a multi-well format, including assays of cell growth rate, influence of various non-parenchymal cell types on tumor behavior, and histology. Thus, a multi-well plate format version of the bioreactor based on microfluidic pumping has been developed (Figure 6). The current prototype has 24 wells in a standard 24-well plate footprint and can be loaded with cells by simple pipetting. We are currently validating that the liver function in this system is comparable to that in the original reactor, using a panel of PCR probes for key P450 enzymes and liver-enriched transcription factors.

Figure 6. Three versions of the bioreactor are currently used for studies. (a) the MilliReactor, which holds 50,000 cells and the Giant reactor, which holds 1.3 million cells (b) The milli reactor in its fluidic circuit, showing the pumps and medium reservoir and battery power (c) the multi-well plate reactor, which can be scaled to hold 10,000 – 1,000,000 cells per well. In (c), colored fluids have been added to the medium reservoir to illustrate the fluid path.

Fig 6 a




Fig 6 b





Fig 6 c



Task 6. Optimize new bioreactor for continuous two-photon imaging. We found that the imaging protocols have very specific demands on reactor construction. Although scaffolds made from plastic materials such as polycarbonate are preferable for histological sectioning, these scaffolds have properties that cause excessive heat generation during 2-photon imaging. We thus have determined that the 2-photon imaging experiments are best conducted with silicon scaffolds, but we have also identified fabrication methods for polymer scaffolds that will allow other experiments to be conducted in a high throughput format.

Task 7. Produce bioreactors and scaffolds for U.Pitt research. This is an ongoing task that generates sufficient bioreactors for studies. To-date, over 25 bioreactor scaffolds and assemblies have been delivered for use in these studies outlined herein. We fabricate silicon scaffolds using deep reactive silicon etching at MIT, and produce these on a semi-high throughput basis. In the past year we have investigated several approaches to fabricating scaffolds from polymers to facilitate histological section and to use in the multi-well plate format of the system. Approaches include laser machining of polycarbonate, polystyrene and polyimide sheets, injection molding of polypropylene, and micromachining of polycarbonate. Among these methods, micromachining of polycarbonate appears the most promising, and we are currently optimizing the methods for ensuring reproducible surface properties.

Task 8. Deconvolute images to determine tumor-hepatocyte involvement and growth dynamics. This will be pursued during year 2. However, initial findings with prostate tumor cells demonstrate close cell-cell contacts between hepatocytes and tumor cells (Figure 7) which will be examined now in the breast cancer containing bioreactors.

Figure 7. Transmission electron micrograph showing close juxtaposition of the tumor cells (T, cell to the left and bottom) with hepatocytes (H, cells to the upper right).



KEY RESEARCH ACCOMPLISHMENTS

- MCF7 breast cancer cells stably expressing GFP and RFP
- Routine isolation of viable hepatocytes and liver endothelial cells
- Routine establishment of mixed hepatocyte and endothelial cell bioreactors
- Production of higher volume bioreactor scaffolds
- Production of 25 bioreactor scaffolds and set ups for experimentation
- Optimization of tumor cell seeding protocol
- Growth of (prostate) tumor cells in the bioreactor
- Demonstration of close contacts between tumor cells and hepatocytes in the bioreactor

REPORTABLE OUTCOMES

Articles:

C Yates, G Papworth, D B Stolz, S Tannenbaum, L Griffith, A Wells (2005). Direct visualization of prostate cancer progression utilizing a novel organotypic liver bioreactor as metastatic target organ. Submitted.

Abstracts:

- C Yates, D B Stolz, L Griffith, A Wells (2004) Direct Visualization of Prostate Cancer Progression Utilizing a Bioreactor. American Association for Cancer Research Annual Meeting, Orlando, FL oral presentation
- C Yates, D B Stolz, L Griffith, A Wells (2005) Ex Vivo Metastasis Model for Prostate Cancer Progression. Regenerate 2005, Atlanta, GA oral presentation
- C Yates, D B Stolz, L Griffith, A Wells (2005) Characterization of Prostate Cancer Progression by Direct Visualization Utilizing a Bioreactor. American Association for Cancer Research Annual Meeting, Anaheim, CA oral presentation

Book chapter:

C Yates, D B Stolz, L G Griffith (2005) Imaging Invasion and Metastasis ex vivo. In Cell Motility in Tumor Progression (ed: A Wells). Kluwer Academic Publishers (Amsterdam). in press

CONCLUSIONS

The first year of this two year award has reached defined milestones and established the base for increasing productivity over the final year of the award. The systems are firmly in place to implement the proposed establishment of this metastasis model system for breast cancer. It has also highlighted new directions for future research in that we find close contacts between hepatocytes and tumor cells.

Importance/Implications: The Key Accomplishments above firmly demonstrate the ability to establish the model system. This provides the 'proof a concept' that such a model system can

examine intermediary scale events during metastatic growth. Further, the finding of close heterotypic cell interactions highlights new avenues for study.

Recommended changes: The results to-date have completed about 2/3 of the key tasks. The findings on heterotypic cell-cell communication have major implications for the regulation of metastatic growth and thus lead us to introduce pilot experiments examining cadherin binding along side the unfinished tasks in year 2.

REFERENCES

1. C Yates, D B Stolz, L G Griffith (2005) Imaging Invasion and Metastasis ex vivo. In Cell Motility in Tumor Progression (ed: A Wells). Kluwer Academic Publishers (Amsterdam). in press
2. J Condeelis, J E Segall (2003). Intravital imaging of cell movement in tumours. *Nature Reviews – Cancer* 3:921-930; J S Condeelis, J Wyckoff, J E Segall (2000). Imaging of cancer invasion and metastasis using green fluorescent protein. *European Journal of Cancer* 36:1671-1680; K J Luzzi, I C MacDonald, et al (1998). Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. *American Journal of Pathology* 153:865-873
3. L G Griffith, B Wu, M J Cima et al (1997). In vitro organogenesis of liver tissue. *Annals of the New York Academy of Sciences* 831:382-397; M J Powers, K Domansky, A Capitano et al (2002) A microarray perfusion bioreactor for 3D liver culture. *Biotechnology and Bioengineering* 78:257-269; M J Powers, D M Janigian, K E Wack et al (2002) Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. *Tissue Engineering* 8:499-513